Partnership will explore AI applications for IBD

Iterative Scopes and Eli Lilly reached a partnership Feb. 11 to conduct research around how artificial intelligence can improve understanding of inflammatory bowel disease pathophysiology and target identification.

Advertisement

IBD research is limited by human interpretation of results. The companies will work together to develop machine learning algorithms to improve on endoscopic clinical trial endpoint assessments.

The ultimate goal is to advance the use of AI for IBD clinical trials.

Jonathan Ng, founder and CEO of Iterative Scopes, said: “This collaboration is an important boost to Iterative Scopes’ efforts to take the collective learnings from the journeys of thousands of patients. Channeling this data into providing the best possible clinical decision for each and every IBD patient.”

More articles on surgery centers:
12-OR ASC part of $295M Florida orthopedic hospital expansion
3 ASCs launching total joint programs
4 ASCs installing total joint robots

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Birmingham (Ala.) Gastroenterology has opened a clinic in Jasper, Ala., expanding access to digestive health services in the region, the…

  • Premier Health Partners has acquired Dayton, Ohio-based Digestive Specialists, according to a notice posted on the website of law firm…

Advertisement

Comments are closed.